Treating a Rare Disease Became a Deliberate Commercial Strategy

The Problem the Law Was Written to Solve

Developing a drug costs about the same amount whether the disease ultimately affects five million people or five thousand. There are still tests to be done. The manufacturing process still needs to be validated. Regulatory review still has to be done page by page. None of it gets cheaper just because fewer people are sick

Before 1983 the predictable result was that most rare diseases went untreated. That was not a story about heartless pharmaceutical companies. It was arithmetic. If a few hundred million dollars of fixed costs cannot be distributed among enough patients no price will recover the money and no company runs a program that loses money by design. Orphan Drug Act was written to change that arithmetic. It defines an orphan disease in the United States as one that affects fewer than two hundred thousand people and provides a specific set of incentives to any company that wants to develop a treatment for one of them

What the Designation Actually Provides

Exclusivity is the piece worth sitting with because it's not a patent and it doesn't behave like one. A competitor can't get approval for the same drug for the same orphan indication for seven years even if no patent covers the molecule at all and even if that competitor developed it completely independently.tracks patent expirations you miss half the picture

There is a related tool that grew alongside the Orphan Drug Act rather than within it: the priority review voucher. A company that wins approval for certain pediatric or rare disease treatments can receive a voucher that entitles any future drug including one that has nothing to do with the rare disease to faster review by the FDA. Those vouchers are transferable. The companies have sold them to other companies on the open market in some cases advertised for very large sumsbecause reducing months of review time for a much larger drug is worth real money. It is a separate program from the 1983 Act but it aims at the same idea. The government has created more than one lever to make work with rare diseases commercially interesting

It Worked, Emphatically

Before the law approvals of treatments for rare diseases came at a rate that could be counted on one hand per decade. Since then approvals designated as orphans number in the hundreds and rare disease research has become one of the most active corners of the entire pharmaceutical industry

Call it what it is. A real political success. Conditions that had nothing now have several treatment options. Patient populations that were commercially invisible the kind that no pharmaceutical company would return a phone call in 1980 became the focus of serious well-funded science. The incentive did exactly what an incentive is supposed to do. I want to say it clearly before I spend the rest of this article on the part that got complicated because it's easy to read an article like this and think that the law wascounterproductive. It didn't. It worked and then continued to work beyond the point everyone expected

Then the Economics Inverted

The part that no one fully took into account was that small populations turned out to bear extraordinarily high prices. When an illness is serious when the drug in front of us is the only option and when the entity that really foots the bill is an insurer or a national health system rather than the patient standing at the pharmacy counter price sensitivity is reduced. No one negotiates hard on the latest treatment out there

A drug that treats five thousand patients for several hundred thousand dollars a year can generate revenue that rivals a mass-market drug sold at regular prices and it gets there with a small sales force a much shorter trial and almost no competition. Rare diseases went from being a category that needed to be subsidized to one of the most attractive segments in the entire industry. I didn't expect that when I first read it. I expected niche markets to stay niches

A Worked Example: Why a Tiny Population Can Outearn a Trial Budget

Numbers make this easier to trust than adjectives so let's build two illustrative drug programs side by side. Neither is a real company. Each figure is a round number chosen to make the mechanism visible and you can check the arithmetic yourself as you go

Program A It is an orphan drug. Suppose that the disease it treats let's call it a very rare metabolic disorder has 8,000 diagnosed patients in the United States. Suppose that in its peak year on the market the drug has captured half of that population so 8,000 times 0.5 gives 4,000 patients on therapy. Set the annual price at $300,000 per patient high but not unusual for a serious andsingle option orphan. Peak annual sales are 4,000 times 300,000 or $1.2 billion

Let us now assume that the trials to obtain Schedule A approval cost in total across all phases $150 million and that the pivotal and supporting studies together enrolled about 200 patients about 2.5 percent of the entire diagnosed population. That enrollment number is small enough to be feasible for such a rare disease which is the point of the exclusivity and the smallest fastest testing pathway that the designation makes available

Program B is a mass-market comparator a drug for a common chronic condition. Suppose 4,000,000 people are diagnosed with this disease so the population it targets is 500 times larger than Schedule A. Put it at $6,000 a year cheap next to Schedule A but normal for a chronic brand-name drug. Suppose it captures a more modest 10 percent of that population at its peak since marketsof chronic diseases are crowded and patients have alternatives. This is 4,000,000 times 0.10 or 400,000 patients and a peak annual sales of 400,000 times 6,000 or 2.4 billion dollars

Getting Program B approved is a bigger task. Let's say its trials cost $1 billion reflecting years of tracking results in about 5,000 enrolled patients the kind of study size regulators expect when a drug competes with existing options rather than being the only one available

Now compare what each program returns for every dollar spent on testing. Program A: 1.2 billion divided by 150 million is 8. Each dollar spent on Program A testing corresponds to $8 of peak annual sales. Program B: 2.4 billion divided by 1 billion is 2.4. Program B is the largest business in absolute terms more than double Program A's peak sales but generates less than a third of the revenue.maximums per test dollar

There is one problem worth mentioning candidly. The cost of trials per enrolled patient is actually higher for Program A: $150 million divided by 200 is $750,000 per patient versus $1 billion divided by $5,000 or $200,000 per patient for Program B. Small trials still involve fixed costs site setup manufacturing validation regulatory filings spread over many fewer.people. What makes Program A attractive is not that it is cheap per patient studied. The point is that the total dollar amount at risk is small enough to be manageable while the price that the market will bear at the other end is high enough that the revenue is not small at all. That gap a small trial budget versus a price that does not have to reduce with the population is the entire business vision that the Orphan Drug Act accidentally created

Case Study: Alexion and the Ultra Rare Disease Playbook

The company most associated with taking this economy as far as it can go is Alexion Pharmaceuticals. Its lead drug Soliris treats paroxysmal nocturnal hemoglobinuria an ultra-rare blood disorder in which a person's own complement system part of the immune response destroys their red blood cells

According to public reports at the time Soliris was routinely described as one of the most expensive drugs in the world priced close to several hundred thousand dollars per patient per year. Alexion built an entire company around that single fact pattern: an ultra-rare disease no real alternative treatment a payer rather than a patient footing the bill and exclusivity protecting the position for years. It's close to the real-world version of Schedule A in the example above a real company that generated billions of dollars.in revenue from a patient population that in absolute terms was small

The market ended up recognizing how valuable that playbook was. AstraZeneca acquired Alexion in a deal announced in December 2020 and closed in 2021 reportedly valued at about $39 billion one of the largest acquisitions in the sector that year. A buyer doesn't pay a sum like that for a drug that treats a small number of patients unless the price per patient and the durability of the position make the economics work which is exactly the investment this article has beendescribing. Alexion did not fall for the ultra-rare disease strategy. It was deliberately built around it and the acquisition price is the market's own verdict on whether that strategy created real value

Salami Slicing and Other Adaptations

Once the incentives were valuable enough a handful of practices emerged that follow the letter of the rules while leaning heavily on their spirit

Indication narrowing It means defining a subset of a common disease often by genetic marker or by disease stage narrow enough that the qualifying population falls below the two hundred thousand threshold. The subset may be scientifically real. It also turns what would otherwise be a mass-market drug into an orphan one with all the associated incentives

Sequential designation It means obtaining orphan status for a narrow indication first and then expanding to progressively broader ones after approval so that a product that was launched as a treatment for rare diseases ends up serving a large population while also receiving rare disease incentives along the way

Reuse It means taking a compound that has already been in use for a long time often cheaply doing the formal trials required by law getting approval and orphan exclusivity for a rare indication and then pricing the newly approved version at a multiple of what patients used to pay for the same molecule. The company actually shouldered the cost of testing and approval which is precisely what the law asked for in exchange for exclusivity. Patients who used to get the compound cheaply experience the result asa price increase for something that already existed not like the arrival of a new medicine

Where the Critics Have a Point

I've laid out the mechanics quite clearly so let me properly argue the other side because critics of this system aren't just being cynical

The strongest version of the criticism is not that companies are breaking a rule. It's that the rule was written for a specific problem a population so small that no ordinary company could justify treating it and past practices avoid the problem statement without violating its text. When a critic calls label narrowing "salami slicing" the charge is that a drug with broad ordinary commercial potential is divided into a narrow genetic or clinical subgroup specifically to qualify for incentives aimed at diseases that had no commercial path at all. IfThe underlying drug would have been developed anyway at normal prices without the orphan designation so the designation is not creating a treatment that would not otherwise exist. It is capturing a subsidy for one that would have arrived anyway and possibly allowing a higher price than a larger undivided indication would ever have supported

The criticism of repurposing is even more acute because it has an identifiable victim: a patient who previously paid very little for a compound and now pays much more for what is chemically the same thing. The company's defense that it bore real costs of the process and that the law explicitly rewards precisely that is legally sound and not dishonest. It is also true that the patient does not experience it as a scientific achievement. They experience it as if their current medication became unaffordable

I think critics go too far in treating every case as bad faith. Genetic subtyping of a disease is often real medicine not a legal trick because a drug that only works for patients with a specific mutation should be labeled and priced based on that population rather than sold indiscriminately to people it won't help. The honest version of this section is that you can't say from the outside in any specific case whether a narrow indication reflects real biology or designed eligibility without doing the clinical homework. ThatAmbiguity is exactly why criticism persists and exactly why it is difficult to write a rule that stops bad cases without also stopping legitimate ones

The Reform Difficulty

Every proposed solution hits the same wall. Tightening eligibility risks depriving the development of genuinely rare diseases that still have no treatment the exact population the law is intended to protect. Directly limiting price is an entirely separate political fight one that extends far beyond orphan drugs to all pharmaceutical prices. It has been proposed more than once to eliminate incentives once a product crosses a certain income threshold and still run into the same objection: that it injectsuncertainty in a decision that a company has to make a decade before the drug is close to being approved when no one can know what the final income will be like

The reforms that have really moved forward tend to be narrow. Clarifying that exclusivity applies to the specific approved use and not the drug as a whole. Closing designations for populations that were never genuinely limited in the first place. None of the solutions touch on the core agreement the law offers and none are likely to change the basic economics this article describes

How I Actually Read an Orphan Drug Portfolio

What I read when I sit down with a company that has real exposure to orphans is that the headline slide tells me almost nothing on its own. I'm looking for four things in order

First what proportion of the portfolio depends specifically on orphan exclusivity as opposed to a patent. These run on different clocks and a company can appear protected for years beyond the point at which its actual moat is exhausted if it is only tracking patents. Second when each exclusivity period actually ends product by product because a company with three drugs whose exclusivity expires in the same eighteen-month period has a concentration problem that a single revenue figure will never tell you.will show. Third whether the population you're targeting is really small or a narrow slice of something larger. This is the hardest to check and the one I spend the most time on because it's where the salami-cutting issue really lies and it usually requires reading the clinical trial's own eligibility criteria rather than relying on the press release

Fourth and I think this is the one that is underweight: the concentration of revenue on a small number of very high-priced products. That's important because a single reimbursement decision by a major payer a national health system deciding a price is too high an insurer tightening a prior authorization requirement can shift a large chunk of a company's revenue in a single announcement. This is a completely different risk profile than a diversified mass-market portfolio where no customer decisionit drives the entire company. Honestly I'm more nervous about underwriting a company with two orphan blockbusters than one with ten mid-size mass-market drugs even when the orphan company's growth numbers look better because the negative case is much more concentrated in a handful of decisions that I can't predict

The way I would actually use this if I were studying a company like this is to treat the exclusivity schedule as the actual earnings model and the current quarter almost as a footnote. I'd rather know what's due in 2029 than what happened last quarter.It's the checklist I make before trusting a growth story based on a small number of very expensive drugs

The Bottom Line

The Orphan Drug Act is a true case study of an incentive that achieves its goal and then continues well beyond it. It made rare disease research viable then it made it lucrative and most of what followed indication narrowing sequential designation repurposing is a legal response to a rule structure rather than an evasion of it. The numbers crunched above show why: a small expensive trial budget compared to a price that doesn't have to.shrinking with population is a genuinely good trade and Alexion's story is evidence that the market will pay enormous sums to own that trade. The political question that remains is not whether treatments for rare diseases will continue to be developed. It is what a treatment should cost once a small population and exclusive position have removed almost all ordinary restrictions on price